Goldman Sachs’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Goldman Sachs’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-111,757	Closed	-$1.17M	–	6191
2023 Q1	$1.17M	Sell	111,757 -6,094	-5%	-$63.1K	﹤0.01%	4271
2022 Q4	$1.21M	Hold	117,851	–	–	﹤0.01%	4300
2022 Q3	$1.18M	Sell	117,851 -707,243	-86%	-$7.07M	﹤0.01%	4395
2022 Q2	$8.23M	Hold	825,094	–	–	﹤0.01%	2691
2022 Q1	$8.15M	Buy	+825,094	New	+$8.14M	﹤0.01%	2896

Other funds holding BIOS

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Quarry LP New York $1.2B AUM 47.63% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Goldman Sachs's BIOS Position: Q2 2023 in Review

Goldman Sachs sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2023, closing a stake of 111,757 shares — an estimated $1.17M sold.

Goldman Sachs first reported a position in BIOS in Q1 2022 and held it in 5 quarters. The position peaked at $8.23M in Q2 2022. 32 funds tracked by Wall St. Rank hold BIOS as of Q2 2023.

Goldman Sachs reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Goldman Sachs sold 111,757 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2023, an estimated $1.17M.
Goldman Sachs first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 5 quarters.
Goldman Sachs's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $8.23M in Q2 2022.
32 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.